Another scenario is a patient who has been using a GLP-1 therapy for a few years, has reached a weight-loss plateau, and is now in the maintenance phase of treatment
, , ,
Subjects were 50 years of age with established CVD (defined as previous CV, cerebrovascular, or peripheral vascular disease), chronic heart failure (New York Heart Association class II or III), or chronic kidney disease (CKD) of stage 3 or higher, or were 60 years of age with at least one CV risk factor (microalbuminuria or proteinuria, hypertension and left ventricular hypertrophy, left ventricular systolic or diastolic dysfunction or anklebrachial index 65 years), and CV risk profile at baseline on time to first occurrence of MACE, the individual components of MACE (CV death, nonfatal MI, or nonfatal stroke), hospitalization for unstable angina or heart failure, and revascularization
In the case of GLP-1 medications, they obtain semaglutide or tirzepatide active pharmaceutical ingredients (APIs) and formulate them into injectable solutions or oral tablets
Semaglutide pulls one lever
[1] mhra.gov.uk or via the Yellow Card app), which helps regulatory authorities monitor medication safety